NCT03472885View on ClinicalTrials.gov

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

September 20, 2019

Study Completion Date

January 5, 2023

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

Danicopan

Participants received a daily oral dose of danicopan TID during the treatment period.

DRUG

Eculizumab

Participants received intravenous eculizumab administered at the participant's usual dose and schedule.

Trial Locations (5)

21287

Clinical Study Site, Baltimore

44195

Clinical Study Site, Cleveland

Unknown

Clinical Study Site, Florence

Clinical Study Site, Naples

Clinical Study Site, London

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY